drugset / Trial / NCT04717466
Brain Changes in Psoriasis After Secukinumab Treatment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
Timeline
- Start
- 2021-06-29
- Primary completion
- 2024-05-16
- Completion
- 2025-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |